Agenus, Inc. (AGEN)
6.70
+0.20
(+3.08%)
USD |
NASDAQ |
Oct 15, 10:02
Agenus Total Long Term Debt (Quarterly) : 259.00M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 259.00M |
| March 31, 2026 | 303.41M |
| December 31, 2025 | 333.86M |
| September 30, 2025 | 339.83M |
| June 30, 2025 | 400.26M |
| March 31, 2025 | 414.41M |
| December 31, 2024 | 428.91M |
| September 30, 2024 | 418.17M |
| June 30, 2024 | 409.30M |
| March 31, 2024 | 344.91M |
| December 31, 2023 | 347.66M |
| September 30, 2023 | 352.03M |
| June 30, 2023 | 352.36M |
| March 31, 2023 | 355.16M |
| December 31, 2022 | 367.97M |
| September 30, 2022 | 348.54M |
| June 30, 2022 | 342.75M |
| March 31, 2022 | 312.64M |
| December 31, 2021 | 310.06M |
| September 30, 2021 | 305.14M |
| June 30, 2021 | 303.84M |
| March 31, 2021 | 296.28M |
| December 31, 2020 | 288.21M |
| September 30, 2020 | 271.26M |
| June 30, 2020 | 265.23M |
| Date | Value |
|---|---|
| March 31, 2020 | 251.25M |
| December 31, 2019 | 243.56M |
| September 30, 2019 | 232.42M |
| June 30, 2019 | 232.96M |
| March 31, 2019 | 230.69M |
| December 31, 2018 | 13.83M |
| September 30, 2018 | 13.74M |
| June 30, 2018 | 13.74M |
| March 31, 2018 | 13.47M |
| December 31, 2017 | 126.83M |
| September 30, 2017 | 111.87M |
| June 30, 2017 | 111.77M |
| March 31, 2017 | 111.67M |
| December 31, 2016 | 112.16M |
| September 30, 2016 | 111.94M |
| June 30, 2016 | 123.27M |
| March 31, 2016 | 118.31M |
| December 31, 2015 | 114.47M |
| September 30, 2015 | 110.70M |
| June 30, 2015 | 11.43M |
| March 31, 2015 | 11.50M |
| December 31, 2014 | 6.027M |
| September 30, 2014 | 6.716M |
| June 30, 2014 | 7.429M |
| March 31, 2014 | 8.147M |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 2.147B |
| Novavax, Inc. | 297.32M |
| AVITA Medical, Inc. | 48.48M |
| Iovance Biotherapeutics, Inc. | 43.33M |
| Amgen, Inc. | 57.30B |